Co-inhibition of menin and FLT3 demonstrated enhanced antileukemia activity in MLL-R/FLT3-mutated and NPM1-mutated/FLT3-mutated AML [65]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.